NCT06688253View on ClinicalTrials.gov

Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

March 30, 2025

Conditions
Myasthenia Gravis Crisis
Interventions
DRUG

IV efgartigimod

IV efgartigimod

Trial Locations (1)

3109601

Rambam- Department of Neurology, Haifa

Sponsors

Collaborators (1)

argenx
All Listed Sponsors
collaborator

argenx

INDUSTRY

lead

Rambam Health Care Campus

OTHER

NCT06688253 - Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis | Biotech Hunter | Biotech Hunter